251 institutions reported holding TARS for 2026Q1, together 105% of the company, more than the 243 a quarter earlier. Institutions reporting a position: 251 (as of 2026Q1). Shares held by institutions: 45.0M, long US equity positions only, as reported on Form 13F. Reported value: $3.16B, at 2026-03-31 prices, not today's. Top 5 holders: 36%, of the whole company, between five filers.

TARSTarsus Pharmaceuticals, Inc.

HealthcareUSD

$70.61

$47.8552 weeks$82.51

Who owns TARS

251 institutions reported holding TARS for 2026Q1, together 105% of the company, more than the 243 a quarter earlier.

251

Institutions reporting a position · as of 2026Q1 · up from 243 the quarter before

Shares held by institutions: 45.0M
Shares held by institutions · 105% of the company · long US equity positions only, as reported on Form 13F
Reported value: $3.16B
Reported value · at 2026-03-31 prices, not today's
Top 5 holders: 36%
Top 5 holders · of the whole company, between five filers

Details›

Reporting quarter2026-03-31: 2026Q1
Quarters on record: 22
New positions: 41
Positions exited: 38
Added to: 81
Reduced: 78
Top 10 holdersof the company: 56%

Institutional ownership by quarter, 2020Q4 to 2026Q1
Quarter	Filers	Shares	Reported value
2026Q1	251	45.0M	$3.16B
2025Q4	243	43.9M	$3.60B
2025Q3	217	44.8M	$2.66B
2025Q2	202	46.0M	$1.86B
2025Q1	192	44.0M	$2.26B
2024Q4	194	40.3M	$2.23B
2024Q3	159	43.3M	$1.42B
2024Q2	146	40.0M	$1.09B
2024Q1	156	39.3M	$1.43B
2023Q4	116	32.2M	$652M
2023Q3	105	29.8M	$529M
2023Q2	92	21.4M	$387M
2023Q1	74	20.1M	$252M
2022Q4	69	20.5M	$301M
2022Q3	75	20.5M	$351M
2022Q2	73	20.0M	$292M

Largest reported holders, 2026Q1
Holder	Shares	% of company	Value
Deep Track Capital, LP	3.6M	8.4%	$253M
BlackRock Inc.	3.6M	8.3%	$249M
RTW INVESTMENTS, LP	3.3M	7.8%	$235M
Paradigm Biocapital Advisors LP	2.6M	6.0%	$180M
VANGUARD GROUP INC	2.4M	5.6%	$169M
HENDERSON GROUP PLC	2.2M	5.2%	$157M
MORGAN STANLEY	1.9M	4.5%	$136M
JENNISON ASSOCIATES LLC	1.7M	4.0%	$120M
Assenagon Asset Management S.A.	1.3M	3.0%	$90M
BANK OF AMERICA CORP /DE/	1.2M	2.8%	$84M

SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold.

reading the register…

Biotechnology

Ranks #69 of 145 by Smart Score

Kailera Therapeutics, Inc.

CLDX+0.92%

Celldex Therapeutics, Inc.

RARE+0.48%

Ultragenyx Pharmaceutical Inc.

VERA+2.5%

Vera Therapeutics, Inc.

TRVI+2.7%

Trevi Therapeutics, Inc.